Marks Group Wealth Management Inc Has $9.88 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Marks Group Wealth Management Inc boosted its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 18.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 43,129 shares of the medical instruments supplier's stock after buying an additional 6,823 shares during the quarter. Becton, Dickinson and Company makes up about 1.0% of Marks Group Wealth Management Inc's holdings, making the stock its 19th biggest position. Marks Group Wealth Management Inc's holdings in Becton, Dickinson and Company were worth $9,879,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of BDX. Smallwood Wealth Investment Management LLC acquired a new stake in Becton, Dickinson and Company in the 1st quarter worth $27,000. REAP Financial Group LLC boosted its position in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares in the last quarter. Alpine Bank Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at about $29,000. Cornerstone Planning Group LLC boosted its position in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 99 shares in the last quarter. Finally, Picton Mahoney Asset Management boosted its position in shares of Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after acquiring an additional 54 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on BDX. William Blair downgraded shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Raymond James Financial downgraded shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Wells Fargo & Company downgraded shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research note on Thursday, May 1st. Barclays dropped their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research note on Tuesday, June 3rd. Finally, The Goldman Sachs Group downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target for the company. in a research note on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $219.22.

Becton, Dickinson and Company Stock Performance

NYSE BDX traded down $1.76 on Monday, hitting $174.21. 2,196,675 shares of the stock were exchanged, compared to its average volume of 2,078,658. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. The business's fifty day moving average is $172.33 and its 200 day moving average is $205.76. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a market capitalization of $49.93 billion, a PE ratio of 33.26, a P/E/G ratio of 1.33 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating the consensus estimate of $3.28 by $0.07. The company had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company's revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm earned $3.17 earnings per share. Research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Monday, June 9th were given a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.39%. The ex-dividend date was Monday, June 9th. Becton, Dickinson and Company's payout ratio is presently 79.39%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP David Shan sold 1,166 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the transaction, the executive vice president directly owned 4,575 shares in the company, valued at approximately $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.